X4 Pharmaceuticals develops and sells oral treatments for rare blood diseases, led by XOLREMDI (mavorixafor) for WHIM syndrome. It last closed at $3.09 on Nov 17, up 9.19% on the day.
XFOR · as of the Nov 17 close · updated after every close
Moving sideways
The stock is 4% below its 20 day and 1% below its 50 day average. It is 22% below its 200 day average, so the longer trend is down. Momentum is fading (RSI 48). The nearest support is the swing low (Oct 29) at $3.05, and the nearest resistance the 50 day average at $3.12.
Short trendNeutral
Long trendBearish
MomentumFading
StretchNormal
VolatilityHigh, 7.8%/day
Key levels
$4.8352 week high+56.3%
$3.77200 day average+22.0%
$3.60100 day average+16.5%
$3.46Swing high (Nov 9)+12.0%
$3.2020 day average+3.6%
$3.18Pivot R1+2.9%
$3.1250 day average+1.0%
$3.09Last close
$3.05Swing low (Oct 29)−1.3%
$3.01Pivot−2.6%
$2.91Pivot S1−5.8%
$2.4352 week low−21.4%
Indicators
RSI (14)
48.23
Middle of its range
Neutral
MACD
-0.01
Below its signal line
Bearish
Stochastic
26.5
Middle of its range
Neutral
ADX (14)
18.7
No clear trend
Williams %R
-59.7
Oversold below −80, overbought above −20
Neutral
CCI (20)
-111.3
Oversold below −100, overbought above 100
Oversold
Rate of change
−2.5%
Change over 10 sessions
Bearish
ATR (14)
$0.24
Typical daily range, 7.8% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
Downtrend
Short trendBearish
Long trendBearish
MomentumWeak
StretchNormal
VolatilityLow, 16.8%/day
Key levels
$4.8352 week high+56.3%
$3.77200 day average+22.0%
$3.60100 day average+16.5%
$3.46Swing high (Nov 9)+12.0%
$3.2020 day average+3.6%
$3.18Pivot R1+2.9%
$3.1250 day average+1.0%
$3.09Last close
$3.05Swing low (Oct 29)−1.3%
$3.01Pivot−2.6%
$2.91Pivot S1−5.8%
$2.4352 week low−21.4%
Indicators
RSI (14)
42.68
Middle of its range
Neutral
MACD
-0.26
Below its signal line
Bearish
Stochastic
32.1
Middle of its range
Neutral
ADX (14)
15.9
No clear trend
Williams %R
-66.3
Oversold below −80, overbought above −20
Neutral
CCI (20)
-75.8
Oversold below −100, overbought above 100
Neutral
Rate of change
−11.7%
Change over 10 sessions
Bearish
ATR (14)
$0.52
Typical daily range, 16.8% of price
MA 10Above
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for XFOR
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how XFOR did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
November seasonalityHow XFOR usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How XFOR has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2017.
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper trading
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether XFOR is in one of them and how their past XFOR trades turned out.
X4 Pharmaceuticals is a biopharmaceutical company based in Boston, Massachusetts, that develops and sells treatments for rare blood diseases. Its main product, XOLREMDI (mavorixafor), is an oral capsule approved in the United States for WHIM syndrome, a rare immune disorder, and patients can obtain it through a specialty pharmacy. The company is also developing mavorixafor for chronic neutropenia, a rare blood condition, and works with partners to commercialize its products outside the United States.